BrainsWay (NASDAQ:BWAY) Issues Earnings Results

BrainsWay (NASDAQ:BWAY) issued its earnings results on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03, Zacks reports. BrainsWay had a return on equity of 3.56% and a net margin of 3.88%. The company had revenue of $10.50 million during the quarter, compared to analysts’ expectations of $10.07 million. During the same period in the prior year, the business earned ($0.01) EPS. BrainsWay updated its FY 2024 guidance to EPS.

BrainsWay Stock Performance

Shares of NASDAQ BWAY traded down $0.66 during mid-day trading on Wednesday, reaching $9.04. 159,185 shares of the company’s stock were exchanged, compared to its average volume of 95,657. The company’s 50-day moving average is $9.11 and its 200-day moving average is $7.40. The firm has a market capitalization of $150.79 million, a price-to-earnings ratio of 91.01 and a beta of 1.25. BrainsWay has a 52-week low of $3.80 and a 52-week high of $10.98.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on BWAY shares. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a report on Monday, October 21st. Northland Securities increased their price target on shares of BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a research note on Thursday, October 3rd.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.